Skip to main content
. 2020 Aug 7;12:7043–7059. doi: 10.2147/CMAR.S252772

Figure 10.

Figure 10

Effect on mice after treatment with the MAPK signaling pathway inhibitor PD325901, pcDNA3.1-IRAK3, and 5-aza-dC. (A) The tumor in the transplantation PD325901, p- IRAK3 + PD325901, and 5-aza-dC + PD325901 treatment groups after 7, 14, 21, and 28 days. (B) The tumor volume was smaller in the PD325901, pcDNA3.1-IRAK3+PD325901, and 5-aza-dC+PD325901 groups compared with the control group. (C) The tumor weight followed the same trend as the volume. (D) The expression level of the IRAK3 was lower in the transplantation PD325901, pcDNA3.1-IRAK3 + PD325901, and 5-aza-dC + PD325901 treatment groups compared with the transplantation control group. (E and F) The protein expression level of IRAK3 was lower in the transplantation PD325901, pcDNA3.1-IRAK3 + PD325901, and 5-aza-dC + PD325901 treatment groups than in the transplantation control group. All the mentioned differences were significant (*P < 0.05, **P < 0.01).